Below are some of the key findings from the esophageal cancer drugs market analysis report
See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.
Global Esophageal Cancer Drugs Industry Overview
Various combinations of drugs such as fluorouracil, cisplatin, docetaxel, and carboplatin are involved in standard chemotherapy regimens for the treatment of esophageal cancer. These drugs are selected based on adverse drug reactions and cancer subtypes. To ensure patient access to available therapeutics, governments in developed countries are introducing reimbursement policies. Medicare comprising of Medicare Part A (hospital insurance) and Medicare Part B (medical insurance) is a federal government program for healthcare in the US that covers chemotherapy for cancer patients. Similarly, the Ministry of Health and Long-term Care in Canada provides funds for CYRAMZA and Health Insurance Review and Assessment Service of South Korea has approved CYRAMZA for the treatment of esophageal cancer. The availability of such favorable reimbursements is one of the critical reasons that will drive esophageal cancer drugs market growth.
Additionally, the use of multimodality treatment approach will also contribute to the growth of the esophageal cancer drugs market which will register a CAGR of over 8% during the forecast period. The optimal treatment of esophageal cancer requires a combination of chemotherapy. This treatment approach aims at providing optimal treatment for esophageal cancer by combining the strengths of various treatments such as chemotherapy and targeted therapy (immunotherapy). It also combines procedures such as perioperative chemotherapy or definitive chemoradiation, radiotherapy, and surgery, which will help improve patient outcome and enhance the survival rate.
Top esophageal cancer drugs companies covered in this market research report
The esophageal cancer drugs market is fairly fragmented. By offering a complete analysis of the market’s competitive landscape and with information on the products offered by companies, this esophageal cancer drugs industry analysis report will help clients identify new growth opportunities and design innovative strategies to improve their share in the market.
The report offers a complete analysis of various companies including:
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd
- Merck & Co., Inc.
- Sanofi
Esophageal cancer drugs market segmentation based on geographic regions
- Asia
- Europe
- North America
- ROW
North America will account for the largest esophageal cancer drugs market share throughout the forecast period. The growth of esophageal cancer drugs market size in this region is due to major factors such as increasing incidence of esophageal cancer, availability of favorable reimbursement schemes, government initiatives, and growing awareness of esophageal cancer.
Esophageal cancer drugs market segmentation based on product
- Targeted therapy
- Chemotherapy
The targeted therapy market segment will account for the highest esophageal cancer drugs market share because of the increasing research on novel drugs. This involves targeting specific proteins such as the vascular endothelial growth factor (VEGF) or human epidermal growth factor receptor 2 (HER2) that contribute to cancer growth and survival.
Key highlights of the global esophageal cancer drugs market for the forecast years 2019-2023:
- CAGR of the market during the forecast period 2019-2023
- Detailed information on factors that will accelerate the growth of the esophageal cancer drugs market during the next five years
- Precise estimation of the global esophageal cancer drugs market size and its contribution to the parent market
- Accurate predictions on upcoming trends and changes in consumer behavior
- The growth of the esophageal cancer drugs industry across various geographies such as Asia, Europe, North America, and ROW
- A thorough analysis of the market’s competitive landscape and detailed information on several vendors
- Comprehensive details on factors that will challenge the growth of esophageal cancer drugs companies
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch